What is OS Therapies's change in accrued liabilities?

OS Therapies (OSTX) reported change in accrued liabilities of $3.88M in Q1 2026.

How has OS Therapies's change in accrued liabilities changed year-over-year?

OS Therapies's change in accrued liabilities increased by 2019.4% year-over-year, from -$202.28K to $3.88M.

What does change in accrued liabilities mean?

Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.

OS Therapies OSTX Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

CTO

Citius Oncology, Inc.CTOR

$19.54M+684%

Avalo TherapeuticsAVTX

-$1.5M+12.1%

ImmunityBio, Inc.IBRX

$3.14M+124%

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+65.5%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's change in accrued liabilities?: OS Therapies (OSTX) reported change in accrued liabilities of $3.88M in Q1 2026.
How has OS Therapies's change in accrued liabilities changed year-over-year?: OS Therapies's change in accrued liabilities increased by 2019.4% year-over-year, from -$202.28K to $3.88M.
What does change in accrued liabilities mean?: Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.